NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
Advertisement
NewsRx | Free Trials
Advertisement
----------
------------
NewsRx on Facebook
-----
Press Release Submissions
PR Login
*
*

Cancer Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Learn More

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now



Brain Cancer



Research from Saarland University reveals new findings on brain cancer



May 12th, 2009

According to a study from Homburg, Germany, "The aim of this study was to evaluate lesion enhancement (LE) and contrast-to-noise ratio (CNR) properties of P846, a new intermediate sized, high relaxivity Gd-based contrast agent at 3 Tesla in a rat brain glioma model, and to compare this contrast agent with a high relaxivity, macromolecular compound (P792), and a standard extracellular Gd-chelate (Gd-DOTA). Seven rats with experimental induced brain glioma were evaluated using 3 different contrast agents, with each MR examination separated by at least 24 hours."

"The time between injections assured sufficient clearance of the agent from the tumor, before the next...


Source: Cancer Weekly (2009-05-12)

NewsRx Passes
Advertisement
More Articles

Related Topics

------------------------
Security by Verisign PR Login